INT1926

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.66
First Reported 1979
Last Reported 2010
Negated 1
Speculated 0
Reported most in Abstract
Documents 54
Total Number 55
Disease Relevance 31.42
Pain Relevance 6.49

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (PLAT) protein modification process (PLAT) extracellular space (PLAT)
extracellular region (PLAT) cytoplasm (PLAT)
Anatomy Link Frequency
plasma 11
blood 3
platelet 2
endothelium 2
visceral 1
PLAT (Homo sapiens)
Pain Link Frequency Relevance Heat
Kinase C 10 100.00 Very High Very High Very High
Inflammatory marker 6 99.76 Very High Very High Very High
Angina 64 99.68 Very High Very High Very High
Inflammatory response 8 99.68 Very High Very High Very High
beta blocker 2 99.28 Very High Very High Very High
aspirin 21 99.04 Very High Very High Very High
substance P 32 98.64 Very High Very High Very High
headache 23 97.64 Very High Very High Very High
anesthesia 16 97.64 Very High Very High Very High
Migraine 152 96.56 Very High Very High Very High
Disease Link Frequency Relevance Heat
Adhesions 83 100.00 Very High Very High Very High
Breast Cancer 28 100.00 Very High Very High Very High
Myocardial Infarction 207 99.96 Very High Very High Very High
Advanced Or Metastatic Breast Cancer 16 99.96 Very High Very High Very High
Recurrence 7 99.96 Very High Very High Very High
Breast Disease 14 99.92 Very High Very High Very High
Coronary Artery Disease 73 99.84 Very High Very High Very High
INFLAMMATION 105 99.76 Very High Very High Very High
Cancer 135 99.74 Very High Very High Very High
Cv General 3 Under Development 60 99.68 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Indeed, in patients treated > 6 hours after infarct in the GUSTO trial, streptokinase produced lower mortality results than accelerated recombinant tissue plasminogen activator (rt-PA).
Positive_regulation (accelerated) of recombinant tissue plasminogen activator
1) Confidence 0.66 Published 1994 Journal Drugs Aging Section Abstract Doc Link 8130384 Disease Relevance 0.53 Pain Relevance 0.13
We have developed a dog model for ex vivo measurement of the fibrinolytic activity using a spectrophotometric assay employing human plasminogen, chromogenic plasmin substrate and human fibrinogen-BrCN digests for the stimulation of t-PA.
Positive_regulation (stimulation) of t-PA
2) Confidence 0.55 Published 1988 Journal Thromb. Res. Section Abstract Doc Link 2840752 Disease Relevance 0 Pain Relevance 0.04
Pretreatment with the beta-blocker propranolol completely blocked the increase in t-PA.
Positive_regulation (increase) of t-PA associated with beta blocker
3) Confidence 0.55 Published 1988 Journal Thromb. Res. Section Abstract Doc Link 2840752 Disease Relevance 0 Pain Relevance 0.05
In the absence of vascular complications, however, only plasma t-PA and PAI-1 levels were significantly increased compared with those in non-diabetic controls.
Positive_regulation (increased) of t-PA in plasma associated with diabetes mellitus
4) Confidence 0.50 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2663449 Disease Relevance 1.05 Pain Relevance 0.03
Pharmacokinetic analysis for functionally active BM 06.022 or alteplase in plasma revealed a total plasma clearance of 4.1-6.6 ml/min/kg for BM 06.022 and of 12.6-42.3 ml/min/kg for alteplase.
Positive_regulation (active) of alteplase in plasma
5) Confidence 0.49 Published 1991 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 1719279 Disease Relevance 0.39 Pain Relevance 0
In the PRIME trial [21], patients (N = 336) with acute MI were randomly assigned to accelerated t-PA and either IV efegatran sulfate (in 1 of 5 doses) or IV heparin.
Positive_regulation (accelerated) of t-PA associated with myocardial infarction
6) Confidence 0.49 Published 2005 Journal Curr Control Trials Cardiovasc Med Section Body Doc Link PMC1236947 Disease Relevance 0.25 Pain Relevance 0.11
In three of the four patients with high PAI and with osteonecrosis present 0.3, 2, and 6 years prior to Stanozolol Rx, there was no clinical improvement after 14-156 weeks of Rx despite normalization of stimulated tPA-Fx and PAI-Fx.
Positive_regulation (stimulated) of tPA associated with aseptic necrosis of bone
7) Confidence 0.49 Published 1995 Journal Am. J. Hematol. Section Abstract Doc Link 7717367 Disease Relevance 0.58 Pain Relevance 0.27
Prior to Rx, mean (SD) stimulated tPA-Fx was low, 0.4 +/- 0.3 IU/ml (lower limit of normal 2.28 IU/ml).
Positive_regulation (stimulated) of tPA
8) Confidence 0.49 Published 1995 Journal Am. J. Hematol. Section Abstract Doc Link 7717367 Disease Relevance 0.38 Pain Relevance 0.06
Prior to Rx, none of the four patients with high PAI-Fx could normally elevate tissue plasminogen activator (tPA-Fx) after 10 min venous occlusion at 100 mm Hg.
Positive_regulation (elevate) of tPA
9) Confidence 0.49 Published 1995 Journal Am. J. Hematol. Section Abstract Doc Link 7717367 Disease Relevance 0.34 Pain Relevance 0
In the CAD patients no significant variation in plasma PAI-1 values could be demonstrated when related to the extent of the disease or to a history of previous myocardial infarction. t-PA antigen was also elevated in CAD patients as compared to the non-CAD group (p less than 0.02).
Positive_regulation (elevated) of t-PA in plasma associated with coronary artery disease, disease and myocardial infarction
10) Confidence 0.49 Published 1990 Journal Thromb. Haemost. Section Abstract Doc Link 2119522 Disease Relevance 1.67 Pain Relevance 0.46
Increased basal values of t-PA antigen (8.2 and 6.6 vs. 4.2 ng/ml) but decreased response after stimulus (2.2 and 1.8 vs. 3.8 ng/ml) and increased levels of lipoprotein(a) (24.7 and 35.9 vs. 10.5 mg/dl) were the most relevant differences between coronary artery disease patients and controls.
Positive_regulation (Increased) of t-PA in coronary artery associated with coronary artery disease
11) Confidence 0.49 Published 1991 Journal Thromb. Res. Section Abstract Doc Link 1836682 Disease Relevance 0.55 Pain Relevance 0.10
RESULTS: The patients had signs of disturbed fibrinolysis, with elevated plasma levels of tissue plasminogen activator (tPA) antigen and plasminogen activator inhibitor (PAI-1) activity at rest, and attenuated responses of tPA antigen and activity to exercise.
Positive_regulation (responses) of tPA in plasma
12) Confidence 0.49 Published 1997 Journal J. Intern. Med. Section Body Doc Link 9042095 Disease Relevance 0.08 Pain Relevance 0
RESULTS: The patients had signs of disturbed fibrinolysis, with elevated plasma levels of tissue plasminogen activator (tPA) antigen and plasminogen activator inhibitor (PAI-1) activity at rest, and attenuated responses of tPA antigen and activity to exercise.
Positive_regulation (elevated) of tPA in plasma
13) Confidence 0.45 Published 1997 Journal J. Intern. Med. Section Body Doc Link 9042095 Disease Relevance 0.09 Pain Relevance 0
Combined accelerated t-PA and eptifibatide in human acute myocardial infarction showed that the restoration of perfusion can be enhanced when eptifibatide is associated with other drugs such as alteplase, aspirin or intravenous heparin factors that can protect the endothelium [19].
Positive_regulation (accelerated) of t-PA in endothelium associated with aspirin and myocardial infarction
14) Confidence 0.43 Published 2002 Journal BMC Cardiovasc Disord Section Body Doc Link PMC117121 Disease Relevance 0.60 Pain Relevance 0.05
In brief, ESCALAT was a randomized, dose-finding study in which intravenous (IV) efegatran sulfate (in 1 of 4 doses) plus streptokinase, or IV heparin plus accelerated tissue plasminogen activator (t-PA) was given to patients (N = 245) presenting with acute STEMI.
Positive_regulation (accelerated) of tissue plasminogen
15) Confidence 0.41 Published 2005 Journal Curr Control Trials Cardiovasc Med Section Body Doc Link PMC1236947 Disease Relevance 0.36 Pain Relevance 0.13
In brief, ESCALAT was a randomized, dose-finding study in which intravenous (IV) efegatran sulfate (in 1 of 4 doses) plus streptokinase, or IV heparin plus accelerated tissue plasminogen activator (t-PA) was given to patients (N = 245) presenting with acute STEMI.
Positive_regulation (accelerated) of t-PA
16) Confidence 0.41 Published 2005 Journal Curr Control Trials Cardiovasc Med Section Body Doc Link PMC1236947 Disease Relevance 0.36 Pain Relevance 0.13
Among 67 patients with metastatic breast cancer, TPA and CEA levels were increased in 70% and 61%, respectively.
Positive_regulation (increased) of TPA associated with advanced or metastatic breast cancer
17) Confidence 0.40 Published 1979 Journal J. Natl. Cancer Inst. Section Abstract Doc Link 292806 Disease Relevance 0.89 Pain Relevance 0.06
CEA levels were not elevated in patients with benign breast disease, but levels of TPA were elevated in 27% of those studied.
Positive_regulation (levels) of TPA associated with breast disease
18) Confidence 0.40 Published 1979 Journal J. Natl. Cancer Inst. Section Abstract Doc Link 292806 Disease Relevance 1.00 Pain Relevance 0.07
Elevation of TPA levels was more frequent in patients with visceral metastasis having higher values of the test results.
Positive_regulation (Elevation) of TPA in visceral associated with metastasis
19) Confidence 0.40 Published 1979 Journal J. Natl. Cancer Inst. Section Abstract Doc Link 292806 Disease Relevance 1.02 Pain Relevance 0.08
TPA levels were elevated (0.09 microgram/ml or higher) in 53% of 19 patients with primary breast cancer, and CEA levels were elevated (2.5 ng/ml) in 21%.
Positive_regulation (elevated) of TPA associated with breast cancer
20) Confidence 0.40 Published 1979 Journal J. Natl. Cancer Inst. Section Abstract Doc Link 292806 Disease Relevance 0.75 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox